The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Liposarcoma


High impact information on Liposarcoma

  • Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma [6].
  • No anti-OS antibody activity was found in sera from healthy individuals or patients with breast carcinoma, clear cell liposarcoma, or leukemia in this study [7].
  • RESULTS: beta-Catenin physically interacted with fusion (FUS)/translocated in liposarcoma (TLS) and various RNA-binding proteins [8].
  • We have conducted a clinical trial for treatment of patients with advanced liposarcoma by using the peroxisome proliferator-activated receptor-gamma ligand troglitazone, in which extensive correlative laboratory studies of tumor differentiation were performed [9].
  • We report here the results of three patients with intermediate to high-grade liposarcomas in whom troglitazone administration induced histologic and biochemical differentiation in vivo [9].

Chemical compound and disease context of Liposarcoma

  • Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor [10].
  • Moreover, primary human liposarcoma cells can be induced to undergo terminal differentiation by treatment with the PPAR gamma ligand pioglitazone, suggesting that the differentiation block in these cells can be overcome by maximal activation of the PPAR pathway [10].
  • CONCLUSIONS: In patients with large, high-grade, primary extremity liposarcoma; DOX is not associated with improved DSS and IF is associated with an improved DSS [11].
  • These animals consistently show the accumulation of a glycoprotein material within the terminally differentiated adipocytes, a characteristic figure of liposarcomas associated with FUS-CHOP [12].
  • Effect of treatment with interferon and cyclophosphamide on the growth of a spontaneous liposarcoma in rats [13].
  • In the present study, we assessed the reproducibility of APB detection on frozen versus formalin-fixed, paraffin-embedded specimens from the same liposarcoma specimens and investigated the eventual stability of ALT in 103 different lesions from 40 adult patients followed during their disease [14].

Biological context of Liposarcoma


Anatomical context of Liposarcoma


Gene context of Liposarcoma


Analytical, diagnostic and therapeutic context of Liposarcoma


  1. NAB2, a corepressor of NGFI-A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuli. Svaren, J., Sevetson, B.R., Apel, E.D., Zimonjic, D.B., Popescu, N.C., Milbrandt, J. Mol. Cell. Biol. (1996) [Pubmed]
  2. SAS amplification in soft tissue sarcomas. Smith, S.H., Weiss, S.W., Jankowski, S.A., Coccia, M.A., Meltzer, P.S. Cancer Res. (1992) [Pubmed]
  3. Chimeric TLS/FUS-CHOP gene expression and the heterogeneity of its junction in human myxoid and round cell liposarcoma. Kuroda, M., Ishida, T., Horiuchi, H., Kida, N., Uozaki, H., Takeuchi, H., Tsuji, K., Imamura, T., Mori, S., Machinami, R. Am. J. Pathol. (1995) [Pubmed]
  4. p53 immunohistochemistry in malignant fibrous histiocytomas and other mesenchymal tumours. Soini, Y., Vähäkangas, K., Nuorva, K., Kamel, D., Lane, D.P., Pääkkö, P. J. Pathol. (1992) [Pubmed]
  5. Alterations of cancer-related genes in soft tissue sarcomas: hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma. Seidel, C., Bartel, F., Rastetter, M., Bluemke, K., Wurl, P., Taubert, H., Dammann, R. Int. J. Cancer (2005) [Pubmed]
  6. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Rabbitts, T.H., Forster, A., Larson, R., Nathan, P. Nat. Genet. (1993) [Pubmed]
  7. Osteosarcoma patients: isolation of serum antibodies by affinity chromatography. Tsang, K.Y., Fudenberg, H.H., Gnagy, M.J. J. Natl. Cancer Inst. (1981) [Pubmed]
  8. beta-catenin interacts with the FUS proto-oncogene product and regulates pre-mRNA splicing. Sato, S., Idogawa, M., Honda, K., Fujii, G., Kawashima, H., Takekuma, K., Hoshika, A., Hirohashi, S., Yamada, T. Gastroenterology (2005) [Pubmed]
  9. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Demetri, G.D., Fletcher, C.D., Mueller, E., Sarraf, P., Naujoks, R., Campbell, N., Spiegelman, B.M., Singer, S. Proc. Natl. Acad. Sci. U.S.A. (1999) [Pubmed]
  10. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Tontonoz, P., Singer, S., Forman, B.M., Sarraf, P., Fletcher, J.A., Fletcher, C.D., Brun, R.P., Mueller, E., Altiok, S., Oppenheim, H., Evans, R.M., Spiegelman, B.M. Proc. Natl. Acad. Sci. U.S.A. (1997) [Pubmed]
  11. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Eilber, F.C., Eilber, F.R., Eckardt, J., Rosen, G., Riedel, E., Maki, R.G., Brennan, M.F., Singer, S. Ann. Surg. (2004) [Pubmed]
  12. Liposarcoma initiated by FUS/TLS-CHOP: the FUS/TLS domain plays a critical role in the pathogenesis of liposarcoma. Pérez-Losada, J., Sánchez-Martín, M., Rodríguez-García, M.A., Pérez-Mancera, P.A., Pintado, B., Flores, T., Battaner, E., Sánchez-Garćia, I. Oncogene (2000) [Pubmed]
  13. Effect of treatment with interferon and cyclophosphamide on the growth of a spontaneous liposarcoma in rats. Marquet, R.L., Schellekens, H., Westbroek, D.L., Jeekel, J. Int. J. Cancer (1983) [Pubmed]
  14. ALT-associated promyelocytic leukaemia body (APB) detection as a reproducible tool to assess alternative lengthening of telomere stability in liposarcomas. Venturini, L., Erdas, R., Costa, A., Gronchi, A., Pilotti, S., Zaffaroni, N., Daidone, M. J. Pathol. (2008) [Pubmed]
  15. Expression of the FUS domain restores liposarcoma development in CHOP transgenic mice. Pérez-Mancera, P.A., Pérez-Losada, J., Sánchez-Martín, M., Rodríguez-García, M.A., Flores, T., Battaner, E., Gutiérrez-Adán, A., Pintado, B., Sánchez-García, I. Oncogene (2002) [Pubmed]
  16. Monoclonality of multifocal myxoid liposarcoma: confirmation by analysis of TLS-CHOP or EWS-CHOP rearrangements. Antonescu, C.R., Elahi, A., Healey, J.H., Brennan, M.F., Lui, M.Y., Lewis, J., Jhanwar, S.C., Woodruff, J.M., Ladanyi, M. Clin. Cancer Res. (2000) [Pubmed]
  17. Evaluation of MDM2 and CDK4 amplification by real-time PCR on paraffin wax-embedded material: a potential tool for the diagnosis of atypical lipomatous tumours/well-differentiated liposarcomas. Hostein, I., Pelmus, M., Aurias, A., Pedeutour, F., Mathoulin-Pélissier, S., Coindre, J.M. J. Pathol. (2004) [Pubmed]
  18. Significance of loss of heterozygosity of the RB1 gene during tumour progression in well-differentiated liposarcomas. Schneider-Stock, R., Boltze, C., Jaeger, V., Stumm, M., Seiler, C., Rys, J., Schütze, K., Roessner, A. J. Pathol. (2002) [Pubmed]
  19. Analysis of FUS-CHOP fusion transcripts in different types of soft tissue liposarcoma and their diagnostic implications. Willeke, F., Ridder, R., Mechtersheimer, G., Schwarzbach, M., Duwe, A., Weitz, J., Lehnert, T., Herfarth, C., von Knebel Doeberitz, M. Clin. Cancer Res. (1998) [Pubmed]
  20. Human liposarcoma cell line, SW872, secretes cholesteryl ester transfer protein in response to cholesterol. Richardson, M.A., Berg, D.T., Johnston, P.A., McClure, D., Grinnell, B.W. J. Lipid Res. (1996) [Pubmed]
  21. Tyrosinase gene expression in human tissues. Battyani, Z., Xerri, L., Hassoun, J., Bonerandi, J.J., Grob, J.J. Pigment Cell Res. (1993) [Pubmed]
  22. The steroid hormone receptors in tumors of adipose tissue. Chaudhuri, P.K., Walker, M.J., Beattie, C.W., Das Gupta, T.K. Journal of surgical oncology. (1985) [Pubmed]
  23. Normal blood lymphocytes from patients with adipose tissue tumors with rearrangements at 12q13-q14 do not express the fragile site fra(12)(q13.1). Turc-Carel, C., Dal Cin, P., Carr, K., Sandberg, A.A. Cancer Genet. Cytogenet. (1988) [Pubmed]
  24. Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma. Dei Tos, A.P., Piccinin, S., Doglioni, C., Vukosavljevic, T., Mentzel, T., Boiocchi, M., Fletcher, C.D. Am. J. Pathol. (1997) [Pubmed]
  25. Role of cholesteryl ester transfer protein in selective uptake of high density lipoprotein cholesteryl esters by adipocytes. Vassiliou, G., McPherson, R. J. Lipid Res. (2004) [Pubmed]
  26. Translocated in liposarcoma (TLS) is a substrate for fibroblast growth factor receptor-1. Klint, P., Hellman, U., Wernstedt, C., Aman, P., Ron, D., Claesson-Welsh, L. Cell. Signal. (2004) [Pubmed]
  27. Expression of multidrug resistance proteins, P-gp, MRP1 and LRP, in soft tissue sarcomas analysed according to their histological type and grade. Komdeur, R., Plaat, B.E., van der Graaf, W.T., Hoekstra, H.J., Hollema, H., van den Berg, E., Zwart, N., Scheper, R.J., Molenaar, W.M. Eur. J. Cancer (2003) [Pubmed]
  28. Nelfinavir induces liposarcoma apoptosis through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6. Guan, M., Fousek, K., Jiang, C., Guo, S., Synold, T., Xi, B., Shih, C.C., Chow, W.A. Clin. Cancer Res. (2011) [Pubmed]
  29. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. Coindre, J.M., Hostein, I., Maire, G., Derré, J., Guillou, L., Leroux, A., Ghnassia, J.P., Collin, F., Pedeutour, F., Aurias, A. J. Pathol. (2004) [Pubmed]
  30. Characterization of centromere alterations in liposarcomas. Sirvent, N., Forus, A., Lescaut, W., Burel, F., Benzaken, S., Chazal, M., Bourgeon, A., Vermeesch, J.R., Myklebost, O., Turc-Carel, C., Ayraud, N., Coindre, J.M., Pedeutour, F. Genes Chromosomes Cancer (2000) [Pubmed]
  31. Activation of metalloproteinases-2 and -9 by interleukin-1alpha in S100A4-positive liposarcoma cell line: correlation with cell invasiveness. Pazzaglia, L., Ponticelli, F., Magagnoli, G., Magagnoli, G., Gamberi, G., Ragazzini, P., Balladelli, A., Picci, P., Benassi, M. Anticancer Res. (2004) [Pubmed]
  32. Iodine-123 BMIPP and Ga-67 scintigraphy in liposarcoma. Yamamoto, Y., Nishiyama, Y., Ono, Y., Fukunaga, K., Satoh, K., Ohkawa, M., Hamamoto, I., Tanabe, M. Clinical nuclear medicine. (1998) [Pubmed]
  33. Distinction of well-differentiated liposarcoma from lipoma in two patients with multiple well-differentiated fatty masses. Yang, Y.J., Damron, T.A., Cohen, H., Hojnowski, L. Skeletal radiology. (2001) [Pubmed]
WikiGenes - Universities